文献速递肝病

肠道微生物组代谢重编程与功能性胆汁酸变化是NAFLD发生的基础

Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
PubMed 文献 · Hepatology · 2022-06-23

该多组学研究对NAFLD不同表型队列的粪便进行16S rRNA测序、微生物转录组学和代谢组学分析,发现源自脱氧胆酸的微生物胆汁酸随疾病活动度和纤维化分期增加,并与微生物胆汁盐水解酶、BaiCD和hdhA表达增加相关;独立NASH临床试验队列证实基线DCA及其结合物与晚期纤维化相关,安慰剂组中纤维化消退者DCA下降而进展者升高,代偿性肝硬化失代偿时DCA进一步升高。

要点

  • 源自DCA的微生物胆汁酸随NAFLD疾病活动度和纤维化分期增加。
  • DCA生成基因相关的拟杆菌门和毛螺菌科多个属随疾病严重度增加。
  • 独立NASH试验中基线DCA及其结合物与晚期纤维化相关。

核心结论

  • 胆汁酸及依赖胆汁酸的微生物组参与NAFLD的发生和进展,为NASH生物标志物开发和治疗提供基础。

研究设计与样本

  • 对具有不同NAFLD表型的队列进行粪便多组学研究,包括16S rRNA测序、微生物转录组学和代谢组学。
  • 另在独立NASH临床试验队列中验证数据的临床相关性。

主要发现

  • 源自脱氧胆酸(DCA)的微生物胆汁酸(甘氨脱氧胆酸、7-酮脱氧胆酸、脱氢胆酸)随疾病活动度和纤维化分期增加。
  • 上述变化与微生物胆汁盐水解酶、胆汁酸操纵子(BaiCD)和羟基类固醇脱氢酶(hdhA)表达增加相关。
  • 含DCA生成基因的拟杆菌门和毛螺菌科多个属随疾病严重度增加,而对DCA抗菌作用敏感的瘤胃球菌科等潜在有益微生物减少。
  • 独立NASH临床试验队列中,入组时DCA及其结合物与晚期纤维化相关。
  • 安慰剂治疗患者中,纤维化消退者DCA下降,纤维化进展者DCA升高;代偿性肝硬化患者发生失代偿时DCA进一步升高。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Bile acids are hepatic metabolites and have many properties considered to be relevant to the pathophysiology of NAFLD. Circulating levels of the intestinal microbiome-modified bile acid deoxycholate are increased in cirrhosis. APPROACH AND RESULTS: To further elucidate the role of bile acids and intestinal microbiota linked to bile acids in progressively severe NAFLD, a multiomic study of feces including 16S rRNA sequencing, microbial transcriptomics and metabolomics was performed in a cohort with varying phenotypes of NAFLD. Several bile acids of microbial origin derived from deoxycholic acid (DCA) (glycodeoxycholate, 7-ketodeoxycholic acid, dehydrocholic acid) increased with disease activity and fibrosis stage. These were linked to increased expression of microbial bile salt hydrolase, bile acid operon (BaiCD) and hydroxysteroid dehydrogenases (hdhA) required for DCA and downstream metabolite synthesis providing a mechanistic basis for altered bile acid profiles with disease progression. Bacteroidetes and several genera of Lachnospiraceae family containing DCA generating genes increased with increasing disease severity, whereas several potentially beneficial microbes sensitive to antibacterial effects of DCA e.g., Ruminococcaceae were decreased. The clinical relevance of these data was confirmed in an independent cohort enrolled in a clinical trial for NASH where at entry DCA and its conjugates were associated with advanced fibrosis. In patients treated with placebo, DCA declined in those with fibrosis regression and increased in those with fibrosis progression. DCA rose further in those with compensated cirrhosis when they experienced decompensation. CONCLUSIONS: These findings demonstrate a role for bile acids and the bile acid dependent microbiome in the development and progression of NAFLD and set the stage to leverage these findings for NASH biomarker development and for therapeutics.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Smirnova E, Muthiah MD, Narayan N, et al. Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD. Hepatology. 2022. PMID: 35561146. doi:10.1002/hep.32568

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。